突变谱分析鉴别TdT阳性高级别/大B细胞淋巴瘤与B淋巴母细胞白血病/淋巴瘤
本研究回顾31例TdT阳性大B细胞淋巴瘤(LBCL)与B淋巴母细胞白血病/淋巴瘤(B-ALL/LBL),发现LBCL各组具有滤泡性淋巴瘤及其高级别转化相关特征性突变及体细胞超突变靶基因变异,而B-ALL/LBL缺乏此类突变。结论提示突变谱分析(含SHM靶基因)对鉴别TdT阳性LBCL与B-ALL/LBL有重要价值。
要点
- TdT在LBCL与B-ALL/LBL均可不同程度表达,免疫表型无明确分界。
- LBCL各组常见滤泡性淋巴瘤相关突变及SHM靶基因变异,B-ALL/LBL缺如。
- 突变谱分析(含SHM靶基因)有助于TdT阳性LBCL与B-ALL/LBL的鉴别。
核心结论
- 包括SHM靶基因在内的突变谱分析对TdT阳性LBCL与B-ALL/LBL的鉴别诊断高度有价值。
研究设计与样本
- 回顾性分析31例TdT阳性LBCL和B-ALL/LBL病例,最终诊断包括19例伴MYC和BCL2重排的弥漫性大/高级别B细胞淋巴瘤(5例DLBCL-MYC/BCL2,14例HGBCL-MYC/BCL2)、3例DLBCL-NOS、3例HGBCL-NOS、4例B-ALL/LBL及2例不可分类病例。
主要发现
- TdT在所有病例中不同程度表达,各组间无明确分界。
- CD20表达丢失或部分丢失见于13/17例DLBCL/HGBCL-MYC/BCL2、2/3例HGBCL-NOS和2/2例不可分类病例,而DLBCL-NOS未见。
- BCL6和/或MUM1表达见于3/4例B-ALL/LBL和2/2例不可分类病例。
- 二代测序显示每例DLBCL/HGBCL-MYC/BCL2均具有滤泡性淋巴瘤及其高级别转化相关特征性突变,且几乎所有DLBCL/HGBCL-MYC/BCL2、DLBCL-NOS和HGBCL-NOS(除1例)存在SHM靶基因频发变异,而B-ALL/LBL无此类突变。
- 2例不可分类病例无特征性突变,其中1例重排IGHV显示中度水平体细胞突变;3例TdT阳性HGBCL-MYC/BCL2的既往或同期滤泡性淋巴瘤研究显示其从IGH::BCL2阳性细胞群获得MYC易位后发生分支演化。
临床怎么用
- 对TdT阳性且形态/免疫表型难以鉴别LBCL与B-ALL/LBL的病例,建议行突变谱分析(含SHM靶基因)辅助诊断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Terminal deoxynucleotidyl transferase (TdT) is occasionally expressed in large B-cell lymphoma (LBCL), and this causes difficulty in differential diagnosis from B-lymphoblastic leukaemia/lymphoma (B-ALL/LBL). We reviewed 31 cases of TdT-positive LBCL and B-ALL/LBL, and their final diagnosis included 19 diffuse large/high-grade BCLs with MYC and BCL2 rearrangements (five DLBCL-MYC/BCL2, 14 HGBCL-MYC/BCL2), three DLBCL not otherwise specified (NOS), three HGBCL-NOS, four B-ALL/LBL, and two unclassifiable cases. TdT was variably expressed in all these cases, without any clear demarcation among different groups. Loss or partial loss of CD20 expression was seen in 13/17 DLBCL/HGBCL-MYC/BCL2, 2/3 HGBCL-NOS, and 2/2 unclassified, albeit not in DLBCL-NOS. Expression of BCL6 and/or MUM1 was seen in 3/4 B-ALL/LBLs and 2/2 unclassified. Next-generation sequencing revealed characteristic mutations associated with follicular lymphoma and its high-grade transformation in each DLBCL/HGBCL-MYC/BCL2, and also frequent variants in genes targeted by somatic hypermutation (SHM) in almost all DLBCL/HGBCL-MYC/BCL2, DLBCL-NOS, and HGBCL-NOS but one case. In contrast, such mutations were absent in B-ALL/LBL. There were no pathognomonic mutations in the two unclassifiable cases, although one showed a moderate level of somatic mutations in its rearranged IGHV. Furthermore, in three cases of TdT-positive HGBCL-MYC/BCL2, studies of previous or concurrent follicular lymphoma demonstrated their divergent evolution from an IGH::BCL2-positive cell population following acquisition of MYC translocation. In conclusion, mutation profiling analysis including the SHM target genes is highly valuable in the differential diagnosis between TdT-positive LBCL and B-ALL/LBL. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
引用
- Tzioni MM, Cucco F, Rásó-Barnett L, et al. Mutation profiling in differential diagnosis between TdT-positive high-grade/large B-cell lymphoma and B-lymphoblastic leukaemia/lymphoma. J Pathol. 2025. PMID: 41047873. doi:10.1002/path.6476
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。